Verified
My morning stiffness eased gradually rather than suddenly. Nausea was noticeable during the first week, then improved when I took the tablet with breakfast.
15 Sept 2026
Active ingredient: Hydroxychloroquine
Plaquenil
Quality products
24/7 Support
Fast delivery
Delivery
from 4 days
Plaquenil is a prescription tablet for people who need treatment or prevention for susceptible malaria or long-term control of rheumatoid arthritis and lupus. Its active ingredient, hydroxychloroquine sulfate, alters parasite survival and immune-cell signalling to help control infection and inflammation.
Description
Plaquenil contains hydroxychloroquine sulfate, supplied as tablets for oral use. Hydroxychloroquine belongs to the 4-aminoquinoline class of antimalarial medicines and also acts as a disease-modifying antirheumatic drug, or DMARD.
Composition
Plaquenil contains hydroxychloroquine sulfate, supplied as tablets for oral use. Hydroxychloroquine belongs to the 4-aminoquinoline class of antimalarial medicines and also acts as a disease-modifying antirheumatic drug, or DMARD.
A DMARD changes inflammatory disease activity rather than only masking pain. Plaquenil may reduce joint swelling and stiffness in rheumatoid arthritis and help control skin or systemic inflammation associated with lupus. Its benefits usually develop gradually, so it is not intended to provide immediate relief from a single painful flare.
Hydroxychloroquine is related pharmacologically to chloroquine, but the medicines have different dosing, resistance considerations, and prescribing instructions. Generic hydroxychloroquine products contain the same active substance, while Plaquenil is the branded product name. The FDA prescribing information identifies hydroxychloroquine sulfate as the active pharmaceutical ingredient [1].
Plaquenil tablets are taken by mouth. Taking the dose with food or a glass of milk can reduce nausea and stomach discomfort.
Dosage and usage
The correct Plaquenil dose depends on the condition, body weight, kidney function, age, treatment duration, and other medicines. The following schedules describe commonly used adult approaches; the prescriber’s regimen takes priority.
- Rheumatoid arthritis: the dose is stated on the pack — follow the leaflet.
- Systemic or discoid lupus: the dose is stated on the pack — follow the leaflet.
- Malaria prevention: the dose is stated on the pack — follow the leaflet.
- Malaria treatment: the dose is stated on the pack — follow the leaflet.
- Children: doses are calculated by body weight. Adult tablets may need careful dose planning because tablet splitting is not always suitable.
- Administration: swallow the tablets orally with food or milk when possible.
- Duration: autoimmune treatment may continue for months or years, while malaria prevention and treatment follow shorter, indication-specific schedules.
Long-term autoimmune treatment should use the lowest dose that maintains disease control. Ophthalmology guidance commonly uses a maximum daily dose based on actual body weight to reduce retinal toxicity risk, with individual prescribing decisions taking kidney function and other risk factors into account [2].
Do not double the next dose after a missed tablet. Take the missed dose when remembered unless the next scheduled dose is close; then continue with the normal timetable.
Plaquenil tablets should not be crushed or chewed unless a prescriber or pharmacist has confirmed that this is suitable. An altered tablet can be harder to dose accurately, especially when a patient needs a weight-based regimen.
Antacids and products containing aluminium, magnesium, or other binding agents can reduce hydroxychloroquine absorption. Separating them from Plaquenil by at least four hours is a common precaution.
How it works
Hydroxychloroquine accumulates inside acidic cellular compartments called lysosomes and endosomes. By raising their internal pH, it changes how certain cells process proteins, antigens, and cellular debris.
The antimalarial effect involves concentration inside the parasite’s digestive vacuole. Plasmodium parasites digest haemoglobin inside red blood cells and produce toxic haem. Hydroxychloroquine interferes with haem detoxification, allowing toxic material to build up inside susceptible parasites.
The immune effects are different. Hydroxychloroquine reduces antigen processing and can dampen signalling through toll-like receptors, especially pathways involving nucleic acids. This reduces activation of inflammatory cells and lowers production of some cytokines.
That mechanism explains why Plaquenil can help lupus and rheumatoid arthritis without being a steroid.
Indications
Plaquenil has three established clinical roles: autoimmune disease management, malaria prevention, and treatment of susceptible malaria infections.
| Indication | Clinical role |
|---|---|
| Rheumatoid arthritis | Long-term DMARD treatment that reduces inflammatory joint activity |
| Systemic or discoid lupus erythematosus | Control of selected skin, joint, and systemic manifestations |
| Malaria | Prevention or treatment when the infecting parasite is susceptible |
Rheumatological applications in autoimmune disorders
In rheumatoid arthritis, hydroxychloroquine is used when inflammatory joint symptoms require disease modification. It may be prescribed alone in milder disease or alongside other antirheumatic treatment. The American College of Rheumatology includes hydroxychloroquine among conventional DMARD options for rheumatoid arthritis.
Systemic lupus erythematosus can affect the skin, joints, blood cells, kidneys, nervous system, and other organs. Plaquenil is commonly used as a long-term treatment for lupus because it can help control disease activity across several symptom patterns. Discoid lupus mainly affects the skin and may also be treated with hydroxychloroquine when topical measures are insufficient.
The medicine does not act like a corticosteroid. It does not provide the rapid anti-inflammatory effect of a steroid injection or high-dose steroid tablets. Its value lies in sustained disease control, with benefit often assessed over several weeks or months.
Parasitic infection management and prophylaxis
Hydroxychloroquine acts against susceptible Plasmodium parasites, including some strains of Plasmodium vivax and Plasmodium falciparum. Resistance is common in many malaria regions, so a prescriber selects prophylaxis or treatment according to travel destination, resistance patterns, illness severity, and the parasite identified.
For adult malaria prevention in an area where hydroxychloroquine remains suitable, a commonly used regimen is 400 mg once weekly. Prevention generally starts before exposure and continues after leaving the malaria area. The timing and duration must be prescribed for the specific travel itinerary. A travel-health or infectious-disease clinician should confirm the regimen before departure.
Treatment doses are different from prevention doses. A common adult treatment schedule for susceptible uncomplicated malaria uses a larger initial dose followed by additional doses over the next two days. Children require weight-based dosing, and the total amount must remain within the prescribed limit. WHO malaria guidance stresses that treatment choice depends on parasite susceptibility and local resistance patterns [3].
Comparison
Plaquenil is an oral, single-ingredient prescription medicine that combines antimalarial activity with disease-modifying effects for selected autoimmune conditions. Its exact dosing and use depend on the indication and the pack leaflet.
Contraindications
Plaquenil is not suitable in these situations
- Previous serious allergy to hydroxychloroquine, chloroquine, or another 4-aminoquinoline.
- Pre-existing maculopathy or retinal disease when the prescriber considers the risk unacceptable.
- Significant heart-rhythm disease or a prolonged QT interval without appropriate specialist assessment.
- Severe kidney impairment unless the dose and monitoring plan have been specifically adjusted.
- Concurrent medicines that create a high risk of QT prolongation or dangerous arrhythmia.
- A history of severe blood disorders linked to hydroxychloroquine.
- Active severe psoriasis or porphyria when the medicine could worsen the condition.
Hydroxychloroquine may interact with amiodarone, sotalol, certain macrolide antibiotics, some antidepressants, antipsychotics, and other QT-prolonging medicines. Combining it with tamoxifen increases concern about retinal toxicity. Digoxin levels can rise, while antidiabetic treatment may need adjustment because hydroxychloroquine can increase insulin sensitivity.
Methotrexate and other immunomodulators may be prescribed with hydroxychloroquine, but the combination requires clinical monitoring.
Pregnancy and breastfeeding require individual assessment. Hydroxychloroquine is used in some autoimmune pregnancies, but the decision depends on disease activity and the treatment plan. The prescriber should know about pregnancy, planned pregnancy, or breastfeeding before therapy starts.
When this is not for you
This treatment is NOT for you if a clinician has identified a serious contraindication, such as unsafe retinal disease or QT prolongation.
You should also speak with a clinician before using it if you have kidney disease, heart-rhythm problems, a history of serious blood disorders, psoriasis, porphyria, or an eye condition. Tell the prescriber if you take tamoxifen, heart-rhythm medicines, certain antibiotics, antidepressants, antipsychotics, digoxin, or diabetes treatment. Pregnancy, planned pregnancy, and breastfeeding require individual medical advice.
Side effects
Many patients tolerate hydroxychloroquine well, yet long-term use requires structured monitoring. The main risks involve the eyes, heart rhythm, skin, blood cells, muscles, and nervous system.
| Possible reaction | Practical significance |
|---|---|
| Nausea, abdominal discomfort, diarrhoea, headache, or skin rash | Often mild, especially early in treatment; food may improve stomach symptoms |
| Blurred vision, difficulty reading, light sensitivity, or colour-vision change | Requires prompt eye assessment because retinal injury may progress without pain |
| Palpitations, fainting, severe weakness, muscle weakness, or breathing difficulty | May indicate cardiac, muscular, or neurological toxicity and needs urgent assessment |
Eye monitoring
Retinal toxicity is uncommon when risk is controlled, but damage can become permanent. Risk rises with prolonged exposure, excessive daily dosing, kidney impairment, tamoxifen use, and pre-existing retinal disease.
A baseline eye examination is usually arranged near the start of long-term therapy. Follow-up screening is commonly performed annually once risk factors or treatment duration justify it. Testing may include visual-field assessment and retinal imaging such as optical coherence tomography. The Royal College of Ophthalmologists and American Academy of Ophthalmology both emphasise objective retinal testing rather than relying only on a basic vision chart.
Report new difficulty reading, missing areas in the visual field, distorted lines, or changes in colour perception promptly. Retinal toxicity can begin without pain or redness.
Cardiac and other adverse effects
Hydroxychloroquine can prolong the QT interval and, rarely, contribute to serious ventricular arrhythmias. The risk is higher with heart disease, low potassium or magnesium, kidney impairment, slow heart rate, or combination with other QT-prolonging medicines.
Rare long-term complications include cardiomyopathy, conduction disorders, severe hypoglycaemia, blood-count abnormalities, muscle weakness, nerve damage, and severe skin reactions. A clinician may order an electrocardiogram, blood count, kidney tests, liver tests, or muscle assessment when the medical history indicates increased risk.
Tell the prescriber about fainting, unexplained palpitations, previous rhythm problems, or a family history of sudden cardiac death before treatment begins.
Common mistakes
- Taking the weekly malaria-prevention dose every day.
- Assuming that a 200 mg tablet always equals a 200 mg daily regimen.
- Stopping Plaquenil after several symptom-free weeks without a treatment plan.
- Missing eye screening because vision feels normal.
- Ignoring new palpitations, fainting, or changes in colour vision.
- Taking antacids at the same time as the tablet.
- Forgetting to mention kidney disease, retinal disease, or tamoxifen use.
- Doubling a dose after a missed tablet.
- Using Plaquenil for COVID-19 or another infection without a prescribed indication.
- Sharing tablets with a family member who has similar joint symptoms.
One practical point is easy to miss: a person can have normal visual acuity and still develop an early retinal field defect. Screening needs more than reading letters from a chart.
Keep a written list of every prescription, over-the-counter medicine, antacid, supplement, and eye product used during Plaquenil treatment.
What doctors say
Rheumatology practice treats Plaquenil as a long-term disease-modifying medicine, not an occasional pain tablet. Doctors generally assess joint symptoms, skin activity, fatigue, blood results, kidney function, and treatment tolerance over time rather than judging success after a few doses.
A common clinical mistake is stopping treatment as soon as symptoms improve. Lupus and rheumatoid arthritis can become active again after treatment is interrupted, even when the person felt well for several months.
The eye examination is part of the treatment plan. It is not reserved for people who already have blurred vision. Baseline retinal assessment and scheduled follow-up allow eye specialists to detect changes before everyday vision is seriously affected.
Physicians also review the complete medication list at each appointment. An antibiotic prescribed for an unrelated infection, a new heart medicine, or tamoxifen can change the safety profile of hydroxychloroquine.
Frequently asked questions
Is Plaquenil a steroid?
Plaquenil is not a corticosteroid; it contains hydroxychloroquine sulfate, an antimalarial and conventional DMARD. It modifies immune signalling over time rather than producing the rapid anti-inflammatory effect associated with steroid treatment. The FDA prescribing information from 2020 lists rheumatoid arthritis and lupus among its established uses. Treatment choice depends on the disease, severity, kidney function, and other medicines.
How long does Plaquenil take to work for rheumatoid arthritis?
Joint symptoms may begin to improve after several weeks, while the full disease-modifying response can take several months. The American College of Rheumatology guideline published in 2021 places hydroxychloroquine among conventional DMARD treatments for rheumatoid arthritis, which are assessed over time rather than after one or two tablets. A lack of immediate relief does not prove that the medicine has failed. Persistent symptoms should be reviewed against disease activity and the treatment plan.
Does Plaquenil damage eyesight?
Plaquenil can cause retinal toxicity, especially with prolonged treatment, excessive dosing, kidney impairment, tamoxifen use, or pre-existing retinal disease. The American Academy of Ophthalmology recommendations published in 2016 support dose-conscious prescribing and retinal screening strategies for people receiving long-term hydroxychloroquine. New visual-field loss, distorted lines, or colour-vision changes need prompt assessment. Do not wait for painful eyes, because retinal toxicity may be painless.
Can Plaquenil be used to prevent malaria?
Hydroxychloroquine can prevent malaria in destinations where the relevant Plasmodium parasites remain susceptible. The WHO malaria guidance published in 2023 explains that resistance patterns determine the appropriate preventive medicine. A commonly used adult prevention schedule is 400 mg once weekly, with the start and stop dates linked to travel. A travel-health clinician should select the regimen according to destination and itinerary.
Can Plaquenil be taken with heart medicines?
Some combinations increase the risk of QT prolongation, conduction problems, or arrhythmia. Medicines such as amiodarone, sotalol, selected macrolide antibiotics, and other QT-prolonging drugs require careful review before hydroxychloroquine is started. The FDA prescribing information from 2020 supports checking the complete medicine list when a product can affect cardiac rhythm. Fainting or sustained palpitations during treatment require urgent medical assessment.
Is Plaquenil used for COVID-19?
Plaquenil is not an approved treatment for COVID-19. The FDA withdrew emergency authorisation for hydroxychloroquine in COVID-19 in 2020 after clinical evidence failed to show the expected benefit. The medicine remains indicated for malaria and selected autoimmune diseases. Taking it for COVID-19 can cause avoidable eye, heart, and interaction risks.
Should Plaquenil be stopped before an eye examination?
Routine eye screening is usually performed while treatment continues, unless an ophthalmologist or prescriber gives a different instruction. The European Medicines Agency referral published in 2019 highlighted the need for retinal monitoring during long-term hydroxychloroquine use [4]. Stopping treatment independently can allow lupus or rheumatoid arthritis activity to return. The eye specialist and prescriber should coordinate any change.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Regulatory status regarding COVID-19
Hydroxychloroquine was investigated for COVID-19 during the early pandemic. Clinical trials did not establish a meaningful benefit for treating or preventing COVID-19, and the FDA revoked its Emergency Use Authorisation for this indication in 2020 [5].
Plaquenil remains a medicine for malaria and selected autoimmune diseases. COVID-19 treatment is not an approved reason to start hydroxychloroquine. Using it for a viral infection can expose a person to retinal, cardiac, and drug-interaction risks without a proven therapeutic benefit.
Plaquenil: Reviews and Experiences
3.8
Based on 4 reviews
Verified
My skin flares became less frequent. I still had fatigue, so Plaquenil was not a complete answer, but the treatment was manageable once I kept the eye appointments.
27 Sept 2026
Verified
I developed blurred vision and contacted the clinic. The eye assessment did not show retinal toxicity, but the dose and other medicines were reviewed.
02 Oct 2026
Verified
The weekly schedule was convenient, but I initially confused the prevention dose with a daily tablet. Writing the dates on a calendar prevented that mistake.
11 Oct 2026
Sources
- U.S. Food and Drug Administration (2020). Plaquenil (hydroxychloroquine sulfate) tablets: Prescribing Information.
- American Academy of Ophthalmology (2016). Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy.
- World Health Organization (2023). WHO Guidelines for Malaria.
- European Medicines Agency (2019). Hydroxychloroquine-containing medicinal products: referral.
- U.S. Food and Drug Administration (2020). Revocation of Emergency Use Authorization for Chloroquine Phosphate and Hydroxychloroquine Sulfate.
